(Q43973627)

28 November 2017

title

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study (English)

1 reference

relapsing-remitting multiple sclerosis

28 November 2017

0 references

0 references

10

Tjalf Ziemssen

1 reference

28 November 2017

3

Hans-Peter Hartung

1 reference

28 November 2017

7

Olaf Stüve

1 reference

28 November 2017

5

Ludwig Kappos

1 reference

28 November 2017

1

Krzysztof Selmaj

1 reference

28 November 2017

11

Lixin Zhang Auberson

1 reference

28 November 2017

9

Xavier Montalban

1 reference

28 November 2017

14

Frank Dahlke

1 reference

28 November 2017

6

Mark S Freedman

1 reference

28 November 2017

4

Bernhard Hemmer

1 reference

28 November 2017

8

Peter Rieckmann

1 reference

28 November 2017

15

Erik Wallström

1 reference

28 November 2017

David K B Li

2

1 reference

28 November 2017

Harald Pohlmann

series ordinal

12

1 reference

28 November 2017

Francois Mercier

series ordinal

13

1 reference

28 November 2017

language of work or name

1 reference

11 June 2013

1 reference

28 November 2017

1 reference

28 November 2017

volume

12

1 reference

28 November 2017

issue

8

1 reference

28 November 2017

page(s)

756-767

1 reference

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

Combining multiple comparisons and modeling techniques in dose-response studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

Risk factors for the development of macular edema in noninfectious uveitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970102-9

7 January 2021

10.1016/S1474-4422(13)70102-9

Identifiers

DOI

1 reference

28 November 2017

1 reference